.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median consequence of 11 months, patients along with metastatic intestinal cysts who acquired biomarker-matched therapies based on circulating cyst DNA profiling presented a better medical perk than those obtaining unparalleled therapy.